Go online to PeerView.com/NDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts provides effective and practical guidance on strategies and techniques for triaging, diagnosing, monitoring, and managing patients who present to the emergency department with immune-related adverse events, as well as special considerations for optimizing the management of oncologic emergencies during the COVID-19 pandemic. Upon completion of this activity, participants will be able to: Interpret the underlying principles of leveraging the immune system in the treatment of cancer and the profiles of immune checkpoint inhibitors, including their characteristics, mechanistic aspects, and regulatory status, Review the biologic reasons and mechanisms that drive the development of immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Describe the spectrum of irAEs associated with the immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency medicine (EM) professionals in the emergency department (ED), Provide an overview of overarching and organ/site-specific recommendations for the identification, assessment, diagnosis/differential diagnosis, and management of irAEs in EM settings, Integrate recommended approaches to triage, evaluation, diagnosis, and management of pertinent irAEs in the ED in collaboration with oncology professionals.
View all episodes
